Replies to post #9856 on GT Biopharma Inc (GTBP)

[legalizeMJ]

r/s is for NASDAQ listing only. NO NEED for r/s any more,here's Why

Oxis International Inc. Announces Approval of FDA Phase 2 Trial with Its Bispecific Antibody OXS-1550

https://finance.yahoo.com/news/oxis-international-inc-announces-approval-123000457.html

relies on highly expensive autologous cell therapies such as presented by Kite Pharma, Inc. (KITE), Juno Therapeutics, Inc. (JUNO)

FYI: Its competitors are KITE, JUNO
Guess What ?
JUNO = $23. per share.
KITE= $75.90 per share.

Dr. Daniel Vallera, director of the section on Molecular Cancer Therapeutics at the University of Minnesota Cancer Center, lead developer of OXS-1550 said, "The FDA's clearance for Phase 2 is an important step forward for this cancer treatment."

Dr. Vallera has spent 35 years with the University of Minnesota's cancer center, where he oversees a laboratory specializing in the development of biological recombinant drugs focusing on bispecific antibody therapies that directly deliver toxic signals to cancer cells.

"We are excited to see this new therapy proceed to Phase 2," Dr. Vallera said. "So many of these patients presenting with chemotherapy refractory cancer have few, if any, alternative choices for cancer treatment."

OXIS= Strong BUY.
$$$$$$$$$$ Go OXIS $$$$$$$$

[Gibba]

Look at what happened after last r/s with less debt.